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Abstract 
Background: This retrospective analysis was undertaken to evaluate the efficiency of SIRT with Y-90 microspheres 
and determined prognostic factors affecting patients with unresectable HCC.
Methods: A total of 97 patients diagnosed with unresectable HCC who underwent SIRT with Y-90 microspheres. 
Patient survival was assessed using the Kaplan–Meier method, and prognostic factors affecting survival were assessed 
using log-rank tests and Cox proportional hazards regression.
Results: Among the 97 patients (90 males, mean age 60.4 ± 12.3 years) who underwent SIRT, the median clinical 
follow-up was 16.4 (1.8–62) months. The median overall survival (OS) was 23.9 ± 2.4 months. Tumor response accord-
ing to the Modified RECIST in patients followed up beyond 6 months included a complete response (CR) to treatment 
in 12 patients (18.8%), partial response (PR) in 23 (35.8%), stable disease (SD) in 8 (12.5%), and progressive disease 
(PD) in 21 (32.8%). Factors associated with longer OS included age > 65 years, BCLC stage B, tumor size < 5 cm, tumor 
burden < 25%, and tumor response (CR/PR). In multivariate analysis, unilobar disease and objective tumor response 
(CR/PR) were predictors of longer OS.
Conclusion: SIRT was an effective treatment for unresectable HCC. Unilobar disease before SIRT and tumor response 
(CR/PR) were positive prognostic factors.
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Introduction
Hepatocellular carcinoma (HCC) is the most common 
primary liver cancer. Worldwide, liver cancers are the 
fourth most common cause of cancer-related deaths. 
Based on annual projections, the World Health Organi-
zation estimates that more than 1 million patients will 
die from liver cancer in 2030. In the United States, the 
proportion of deaths owing to liver cancer increased by 
43%, from 7.2 to 10.3 deaths per 100,000, between 2000 
and 2016, with a 5-year survival rate of 18% [1]. However, 
only 20–30% of HCC patients are diagnosed at an early 
stage; most (> 70%) patients are diagnosed with unresect-
able disease and have poor overall prognosis [2]. Radi-
cal therapies, including resection or transplantation, are 
the gold standard for early-stage HCC [3]. Locoregional 
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therapies such as transarterial embolotherapies, includ-
ing conventional transarterial chemoembolization 
(TACE), bland transarterial embolization, and drug-
eluting bead TACE (DEB-TACE) have played an increas-
ingly important role for patients with unresectable HCC. 
Targeted molecular therapies also have a recognized 
role, with sorafenib (regorafenib and lenvatinib) showing 
improved survival in advanced HCC patients [4]. SIRT 
with yttrium-90 (Y-90) microspheres is another feasible 
treatment option for this patient group, with a disease 
control rate of approximately 80% [5]. SIRT is usually 
indicated for intermediate- or advanced-stage patients 
who are poor candidates for TACE because of massive 
tumors, bilobar disease, or portal vein thrombosis (PVT). 
SIRT is also the treatment of choice for patients who are 
slightly above the criteria for curative treatments and 
who require tumor down-staging [6]. In recent years, 
SIRT with Y-90 microspheres has been proposed as an 
alternative to TACE. Several reports have shown that 
compared with TACE, SIRT is safe, with a lower rate of 
embolic complications such as fever and abdominal pain. 
SIRT is a recommended treatment for advanced HCC 
patients with PVT and has been shown to be efficacious, 
with comparable tumor response and survival rates to 
those of TACE [6]. This study evaluated the efficacy and 
safety of SIRT for unresectable HCC patients and ana-
lyzed prognostic factors affecting overall survival (OS) in 
this group of patients.
Patients and methods
Patients
We enrolled 97 unresectable HCC patients who under-
went SIRT with Y-90 microspheres (SIR-spheres, Sir-
tex Medical, Sydney, Australia) at a single institution 
between October 2013 and March 2019. Starting in 
October 2013, all consecutive patients with HCC who 
were unsuitable for radical treatments (surgery, liver 
transplantation, or percutaneous ablation) or chemoem-
bolization as a result of the presence of PVT or extensive 
tumor burden were assessed for SIRT. The inclusion cri-
teria were patients diagnosed with HCC not amenable 
to curative surgical resection; at least 18  years of age; 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 0–2; Child–Pugh score ≤ 7; life expec-
tancy > 3  months; without extrahepatic tumor burden; 
arteriovenous lung shunting < 20% in 99mTc-macroag-
gregated albumin (MAA); and adequate hematology 
(granulocyte count ≥ 1.5 ×  109/L, platelets ≥ 50 ×  109/L), 
renal function (creatinine level ≤ 176.7  µmol/L), hepatic 
function (bilirubin level ≤ 2  mg/dL), and transaminase 
levels < 5 times the institutional upper limit of the nor-
mal range. All patients provided informed consent. The 
exclusion criteria were infiltrative tumor type; tumor 
volume > 75% of the target liver volume or tumor nodules 
too numerous to count; tumor volume > 50% combined 
with an albumin level < 3.0 mg/dL; ascites or clinical liver 
failure; pre-assessment angiogram showing abnormal 
vascular anatomy that would result in significant reflux of 
hepatic arterial blood to the stomach, pancreas, or bowel; 
disseminated extrahepatic malignant disease; prior 
external beam radiotherapy involving the liver; female 
patients who were pregnant or lactating; and severe 
comorbidities.
The study protocol was performed according to the 
principles of the 1975 Declaration of Helsinki and the 
study was approved by the Institutional Review Board 
of 108 Military Central Hospital (No;3761/HDDD). 
Informed consent was obtained from all individual par-
ticipants included in the study.
Methods
The study was designed as a retrospective investigation. 
The radioembolization agent was Y-90 Resin Micro-
spheres (SIR-Spheres®, Sirtex Medical Limited, Sydney, 
Australia) made of 20–60-μm-sized resin or polymer 
beads with a high-energy, beta-emitting isotope without 
primary gamma emission [7].
Y-90 resin SIRT protocol: patients underwent com-
prehensive pretreatment evaluations comprising medi-
cal history, physical examination, and laboratory and 
imaging workup to confirm treatment eligibility. Diag-
nostic angiography accompanied by 99mTc-MAA 
scintigraphy was then performed to identify vascular 
anatomy, HCC feeding vessels, aberrant vessels and 
extrahepatic collateral vessels feeding extrahepatic 
organs (especially the gastrointestinal tract), and the 
presence of intrahepatic or intratumoral arterioportal 
shunting; and, in case of PVT, the presence of bypass-
ing blood flow through collateral vessels. Aberrant 
hepatic vessels and extrahepatic collaterals were coil-
embolized to prevent the inadvertent misplacement of 
90Y resin microspheres into the gastrointestinal tract 
or pancreas. 99mTc-MAA particles were then injected 
with the delivery catheter in the intended position for 
90Y resin microsphere infusion. Single-photon emis-
sion CT (SPECT) images were acquired to evaluate the 
3D distributions of the microspheres inside the tumor 
and surrounding liver. The scintigraphy studies were 
usually performed within 1 h after 99mTc-MAA injec-
tion to assess pulmonary shunt and any unintended 
flow to other extrahepatic organs. Any patient who 
exhibited an intense mismatch between intrahepatic 
99mTc-MAA distribution and liver lesions as viewed on 
fusion imaging with SPECT and CT was ineligible for 
treatment. The doses of resin microsphere treatments 
were calculated to maximize the therapeutic activity to 
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tumorous tissue and minimize exposure of nontumoral 
parenchyma and lung tissue. Within 1 week after MAA 
angiography, SIR-Spheres® were administered follow-
ing the same route used for MAA. Treatment protocol 
was approved institutionally.
Data collection and follow-up: the following data 
were collected at baseline: age, sex, presence of cirrho-
sis, PVT (segmental, branch, or main) and liver disease 
involvement (left lobe, right lobe, both lobes), extent of 
hepatic involvement (number and size of nodules) via 
CT, laboratory parameters including complete blood cell 
count, liver function tests, serum creatinine, Anti-HCV 
antibodies, hepatitis B surface antigen, ECOG, BCLC 
stages and Child–Pugh scores. Adverse events were clas-
sified for according to Common Terminology Criteria 
for Adverse Events, version 3.0. Tumor response follow-
ing SIRT was assessed at 3 and 6  months by CT scan. 
In the evaluation of tumor response, the parenchymal 
and intravascular components of disease were assessed. 
With regards to changes in size of target lesions assessed 
according to mRECIST (8) in those patients with meas-
urable disease, and the development of new lesions was 
assessed in all patients. If patients had PVT, changes in 
the extent of PVT were evaluated and classified as par-
tial response (clearance or regression of tumor thrombus 
into a more distal portal vein segment), stable disease (no 
changes), or progressive disease (progression of tumor 
thrombus into a more proximal portal vein segment). 
Eventually, overall response was established as progres-
sive disease whenever a patient had tumor progression in 
any of the three individual parameters (measurable target 
lesions, new lesions, or tumor thrombus) and controlled 
disease in any other case. Survival was determined from 
the time of treatment until death. Patients lost to follow-
up were censored at the date of their last known visit.
Statistical analysis
Descriptive statistics for nominal, ordinal, and continu-
ous variables, including frequency, median, and average, 
were used as appropriate. Proportions were compared 
using chi-squared tests with continuity correction or 
Fisher’s exact tests, as appropriate. Survival was calcu-
lated from the day of treatment using the Kaplan–Meier 
method, and subgroup comparisons were performed 
using log-rank tests. We assessed the predictors of sur-
vival using univariate and multivariate Cox proportional 
hazard regression analyses. To assess the variation in 
each liver function test over the previous follow-up, we 
used one-way analysis of variance. The analysis was per-
formed using IBM SPSS Statistics for Windows, version 
20.0 (SPSS GmbH, Munich, Germany). Significant differ-
ences were defined as p < 0.05.
Results
Patient characteristics at baseline
Overall, 97 patients with HCC underwent treatment with 
Y-90 microspheres with the median follow-up period 
for all patients after SIRT was 16.4  months (range 1.8–
62  months). Ten patients were lost to follow-up within 
3  months after TARE. Twenty-three patients who had 
non-measurable parenchymal target disease (diffuse or 
massive tumors) did not perform computerized tomogra-
phy at 6 months after TARE. It was impossible to evalu-
ate for tumor response.
The mean age was 60.4 ± 12.3 (range 25–89) years; 
90 patients were male (92.8%) and about half of them 
were positive for hepatitis B. Most patients had ECOG 
1 (73.2%); 19.6% received prior treatments, including 
resection, radiofrequency ablation, percutaneous etha-
nol injection therapy, and TACE. Ninety-one patients 
(93.8%) had a Child–Pugh score of A. Barcelona Clinic 
Liver Cancer (BCLC) stage C (n = 59, 60.8%) was more 
common than BCLC B (n = 38, 39.2% and 61 patients 
(62.9%) had portal vein invasion. The mean tumor size 
was 10.2 ± 3.5 cm. The disease was limited to one lobe in 
81 patients, and 16 patients had bilobar disease (Table 1). 
The mean dose of Y-90 was 1.6 ± 0.6 GBq, with an esti-
mated 5.2 ± 3.6% being shunted to the lungs.
Treatment response
Among all patients, 64 were followed up beyond 
6  months after radioembolization therapy and under-
went follow-up CT based on which tumor response was 
assessed according to the RECIST guidelines. Complete 
response (CR) and partial response (PR) to treatment 
were observed in 12 (18.8%) and 23 patients (35.8%), 
respectively, while 8 (12.5%) and 21 (32.8%) patients, 
respectively, had stable disease (SD) and progressive dis-
ease (PD). The tumor diameter decreased from a mean of 
10.2 ± 3.5 cm at baseline to 6.9 ± 3.3 cm at 6 months after 
treatment (Table 2).
The median survival after SIRT was 23.9 months, with 
the 6-, 12-, 24-, 36- and 48-month survival rates being 
77.9%, 56.7%, 39.2%, 31%, and 18.5%, respectively (Fig. 1). 
Two patients had SD, with a survival of 48  months. 61 
patients died 1 – 48 months after SIRT. In 53 of the 61 
patients who died, tumor progression was the suspected 
cause of death. Sites of progression included target 
lesions (n = 20), new lesions (n = 12), tumor thrombus 
(n = 9) and extrahepatic metastases (n = 12). Among the 
64 patients who reached 6-month follow-up and were 
evaluable for response, 21 (32.8%) had progressive dis-
ease. Sites of progression included new lesions (n = 19) 
and tumor thrombus (n = 2).
Overall, univariate analysis of OS showed signifi-
cant interrelations between age, tumor size, tumor 
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burden, tumor distribution, BCLC stage, and radiologi-
cal response to treatment. Survival did not differ signifi-
cantly in subgroups of patients according to sex, ECOG 
score, prior treatment, portal vein invasion, alpha-feto-
protein (AFP) level, and Child–Pugh score (Table 3).
Significant differences were noted in terms of survival 
during 5 years follow-up between Kaplan–Meier survival 
curves of the two groups according to age, BCLC stage, 
tumor burden and objective tumor response (Fig. 2a–d), 
using the log-rank test (p value = 0.017, 0.018, < 0.001, 
and < 0.001, respectively).
In multivariate analysis, the tumor distribution (haz-
ard ratio [HR] for unilobar vs. bilobar; 0.10, confidential 
interval; 0.02–0.75, p = 0.012) and best overall mRECIST 
response (HR for CR/PR vs SD/PD; 0.09, confidential 
interval; 0.03–0.29, p = 0.001) were independent predic-
tors of OS (Table 3).
Clinical toxicity
In total, 38 (39.2%) patients developed clinical toxicity 
after treatment, which included abdominal pain (n = 25, 
25.8%), fatigue (n = 19, 19.6%), fever (n = 6, 6.2%), and 
nausea/vomiting (n = 6, 6.2%). These complications were 
Table 1 Baseline characteristics
Variables N = 97 (%)
Age, years
  < 65 61 (62.9)
  ≥ 65 36 (37.1)
Sex
 Male 90 (92.8)
 Female 7 (7.2)
Etiology
 Hepatitis B 54 (55.7)
 Hepatitis C 4 (4.1)
 Alcohol 3 (3.1)
 Unknown 36 (37.1)
Performance status
 0 14 (14.4)
 1 71 (73.2)
 2 12 (12.4)
Prior treatment
 None 78 (80.4)
 Resection 5 (5.2)
 Radiofrequency ablation 3 (3.1)
 Percutaneous ethanol injection therapy 2 (2.1)
 Transarterial chemoembolization 9 (9.3)
Method of diagnosis
 Liver biopsy 59 (60.8)
 Imaging 38 (39.2)
Pathology
 Well-differentiated 10 (10.3)
 Moderate differentiated 38 (39.2)
 Poorly differentiated 3 (3.1)
 No defined 8 (8.2)
Cirrhosis on imaging
 Present 94 (96.9)
 Absent 3 (3.1)
Tumor distribution
 Unilobar, right 74 (76.3)
 Unilobar, left 7 (7.2)
 Bilobar 16 (16.5)
Portal vein invasion
 None 36 (37.1)
 Below subsegmental 1 (1.0)
 Subsegmental 28 (28.9)
 Lobar 25 (25.8)
 Main 7 (7.2)
Index lesion size (cm)
 < 5 6 (6.2)
 5–10 40 (41.2)
 > 10 51 (52.6)
Tumor burden* (%)
 < 25 44 (45.4)
 25–50 38 (39.2)
Table 1 (continued)
Variables N = 97 (%)
 > 50 9 (9.3)
 No defined 6 (6.2)
Alpha-fetoprotein
 < 100 45 (46.4)
  ≥ 100 52 (53.6)
Total bilirubin (mg/dL)
 < 2 93 (95.9)
 2–-3 4 (4.1)
 > 3 0 (0)
Albumin (mg/dL)
 > 3.5 83 (85.6)
 2.8–3.5 12 (12.4)




 C 0 (0)
BCLC† stage
 A 0 (0)
 B 38 (39.2)
 C 59 (60.8)
 D 0 (0)
*Tumor burden, Tumor volume/liver volume
† BCLC, Barcelona Clinic Liver Cancer staging system
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mild and resolved without active intervention. No patient 
died because of the treatment.
During follow-up, one patient experienced gastroduo-
denal ulceration, one experienced pneumonitis, and one 
experienced gastrointestinal (GI) bleeding 3  months 
after SIRT. Two patients developed GI bleeding after 
6 months.
Discussion
For many HCC patients, curative surgical therapies 
(resection or transplantation) are not an option owing 
to tumor bulk or the presence of metastatic disease. 
Locoregional therapies such as SIRT with Y-90 are via-
ble alternative methods of reducing tumor burden, pro-
longing OS, and improving quality of life. Our study 
demonstrated that SIRT administered to 97 patients 
with unresectable HCC resulted in a median survival of 
23.9 months, with a 3-year survival of 31%. Our encour-
aging findings are concordant with those reported in 
earlier series. Salem et al. reported a median survival of 
20.5  months and 3-year survival of 25% in 123 patients 
who underwent SIRT [8]. Mantry et  al. reported a 
median survival of 13.1  months in 111 patients treated 
with SIRT [9]. In the ENRY study, a prospective Euro-
pean multicenter trial of Y-90 resin SIRT in 325 patients 
with unresectable HCC, the median OS was 12.8 months 
(95% confidence interval [CI]: 10.9–15.7) [10]. However, 
other studies reported longer OS. For instance, Saxena 
et  al. reported a median OS of 27.7  months and 3-year 
survival of 26% in 45 patients with unresectable HCC [6]. 
A meta-analysis of 21 published reports showed that the 
pooled OS was 63% and 27% at 1- and 3-years respec-
tively in intermediate-stage HCC, whereas OS was 37% 
and 13% at 1- and 3-years respectively in advanced HCC 
because of the presence of portal vein thrombosis [11].
In patients with advanced HCC, sorafenib has become 
the standard treatment after the SHARP trial showed a 
higher median OS for sorafenib (10.7  months) than for 
placebo (7.9  months) [12]. The SARAH trial demon-
strated similar OS between patients treated with SIRT 
and sorafenib (8.54 vs. 10.58 months), however, a lower 
rate of serious adverse events was observed in the Y-90 
arm (27%) than in the sorafenib arm (> 50%). In addi-
tion, the tumor response rate was better in the Y-90 arm 
(16.5%) than in the sorafenib arm (1.7%) [7]. Collectively, 
these data support the role of SIRT rather than systemic 
agents in the management of unresectable HCC, when-
ever possible.
The current recommended TACE is the stand-
ard of care and first-line treatment for intermediate-
stage unresectable HCC [13]. The median survival is 
around 20  months in most series, ranging from 14 to 
45  months [14]. Several studies comparing the rela-
tive efficacy of SIRT and TACE showed that SIRT is 
as effective, if not more effective, in inducing a radio-
logical response and improving survival than TACE 
[15]. Clinically, most of the disadvantages of TACE 
manifest as pain and post-embolization syndrome, 
often requiring hospitalization. Moreover, TACE is 
contraindicated in patients with main PVT because of 
its profound ischemic effects. Salem et  al. compared 
the results of 122 patients who underwent SIRT with 
those of 123 patients treated with TACE [8]. Compli-
cations, particularly, abdominal pain and liver dys-
function were more common following TACE than 
Table 2 Tumor response based on mRECIST guidelines
*mRECIST, Response Evaluation Criteria In Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease
Time point Lesion diameter (cm), 
mean ± standard deviation
Number with available 
data (N = 97) 
mRECIST*, n (%)
CR PR SD PD
Baseline 10.2 ± 3.5 97 – – – –
3 months 8.2 ± 3.5 87 10 (11.5) 42 (48.3) 19 (21.8) 16 (18.4)
6 months 6.9 ± 3.3 64 12 (18.8) 23 (35.9) 8 (12.5) 21 (32.8)
Fig. 1 Kaplan–Meier survival curves. (A) Median overall survival was 
23.9 months. The median survival after SIRT was 23.9 months with 6-, 
12-, 24-, 36-, and 48-month survival of 77.9%, 56.7%, 39.2%, 31%, and 
18.5%, respectively
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following SIRT (p < 0.05). A trend toward higher objec-
tive response rates (49 vs. 36%, p = 0.1) was observed in 
patients undergoing SIRT. The time-to-progression was 
longer following SIRT than following TACE (13.3 vs. 
8.4 months, p = 0.046); however, the median OS did not 
differ significantly (20.5 vs. 17.4  months, p = 0.2). Par-
ticularly, in meta-analysis of 10 published reports, SIRT 
showed a statistically significant benefit as compared 
to TACE in terms of higher progression-free survival 
rate, although SIRT and TACE showed similar overall 
survival [16]. These studies illustrated better quality of 
life outcomes in patients undergoing SIRT rather than 
those undergoing TACE, although more patients pre-
sented with advanced disease.
In the univariate analysis, the prognosticators of 
OS were age, tumor size, liver tumor burden, tumor 
distribution, BCLC stage, and radiological response to 
treatment. Patients older than 65 years fared better than 
their younger counterparts, likely because the proportion 
BCLC B patients older than 65 years was higher than that 
in younger patients (55.6% vs. 36.1%, p = 0.061). Consid-
ering recent reports, radioembolization appears to be a 
well-tolerated and effective treatment option for elderly 
patients without concomitant disease [8, 17]. In our 
study, the median OS was significantly better in patients 
with BCLC stage B than in those with stage C (31.2 vs. 
21.2  months; p = 0.018). Salem et  al., Ozkan et  al., and 
Sangro et al. also emphasized the significant relationship 
between BCLC stage and survival [8, 10, 18]. Multivariate 
analysis in the present study showed that unilobar tumor 
distribution and tumor response were prognostic factors 
for OS. This finding was expected and has been reported 
Table 3 Significant predictors of survival
*HR, hazard ratio; CI, Confidential Index
† Tumor burden, Tumor volume/liver volume
‡ BCLC, Barcelona Clinic Liver Cancer staging system
§ mRECIST, Response Evaluation Criteria In Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease
Variables Univariate analysis Multivariate analysis
HR (95% CI)* p Value HR (95% CI) p Value
Age  < 65 1.97 (1.12–3.46) 0.017
 ≥ 65 1
Sex Male 1.25 (0.45–3.49) 0.661
Female 1
ECOG 0, 1 1
2 1.39 (0.18–6.67) 0.732
Prior treatment No 0.96 (0.51–1.81) 0.893
Yes 1
Tumor distribution Unilobar 0.87 (0.43–0.98) 0.044 0.10 (0.02–0.75) 0.012
Bilobar 1
Portal vein invasion No 0.61 (0.35–1.06) 0.083
Yes 1
Index lesion size (cm)  ≤ 10 0.39 (0.22–0.67) 0.001 0.92 (0.26–3.21) 0.672
 > 10 1
Tumor  burden† (%)  ≤ 50 0.18 (0.07–0.43) 0.001 0.94 (0.58–9.52) 0.733
50–75 1
Alpha-fetoprotein  < 100 0.63 (0.38–1.05) 0.072
 ≥ 100 1
Child–Pugh class Child A 1
Child B 1.27 (0.40–4.06) 0.691
BCLC  stage‡ BCLC B 0.48 (0.26–0.89) 0.018 0.43 (0.12–1.15) 0.317
BCLC C 1
Radiologic response  (mRECIST§) CR/PR 0.14 (0.06–0.32) 0.001 0.09 (0.03–0.29) 0.001
SD/PD 1
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previously. Mazzaferro et  al. showed that radiological 
response (CR/PR/SD vs. PD) was an independent risk 
factor for OS (p = 0.048) [19].
In this study, the clinical toxicity rate was 39.2%, and 
all events, including abdominal pain, fatigue, fever, and 
nausea/vomiting, were self-limiting and resolved with-
out active intervention. No treatment-related mortality 
was observed, similar to reports from earlier series[6, 
8]. During the follow-up, one patient developed dysp-
nea 3  months after radioembolization, suggesting 
radiation-induced pneumonitis. One patient presented 
with gastroduodenal ulceration and one case had variceal 
esophagus bleeding 3 months after treatment. At 6 weeks 
after SIRT, two patients developed GI bleeding owing to 
hepatic failure. Mayer et al. reported about three patients 
with gastroduodenal ulcers, one with radiation pneumo-
nitis, and one with septicemia [20].
Our study also has some limitations. First, the ret-
rospective nature of this study and the relatively small 
sample size obviously limits the strength of evidence. 
Fig. 2 Kaplan–Meier curves demonstrating survival based on age, BCLC stage, tumor burden, and tumor response. a The median overall survival 
is significantly better in patients aged above 65 years than in those aged below 65 years (30.5 vs. 19.1 months; p = 0.017). b The median overall 
survival was significantly better in patients with BCLC stage B than in those with BCLC stage C (31.2 vs. 21.2 months; p = 0.018). c The median overall 
survival was significantly better in patients with tumor burden under 25% than in those with tumor burden 25–50% and above 50% (33.1, vs. 15.9 
and 9.7 months; p < 0.001). d The median overall survival was significantly better in patients with objective tumor response (CR/PR) than in those 
with SD/PD (40.1 vs. 16.3 months; p < 0.001)
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Second, the median follow-up period for all patients was 
too short. In particular, the presence of a high percent-
age of patients for whom the tumor response could not 
be evaluated. It is expected to have affected these results. 
The hazard ratios of the tumor distribution and the best 
overall mRECIST response (CR/PR) were likely to be 
overestimated. It is another limitation for the results of 
this study. Third, we were not able to analyze the severity 
of non-laboratory adverse events because the description 
of the adverse events is not properly recorded. Finally, the 
Kaplan–Meier method is the most commonly used time-
to-event analysis. However, since not all the patients died 
because of cancer, a survival method that considers the 
competing risk would be more appropriate.
Conclusions
Our study results add to the growing literature on SIRT for 
unresectable HCC, demonstrating that SIRT is safe and 
effective with high objective response rates (CR/PR 54,7%) 
and median OS of 23.9  months. The unilobar disease 
before SIRT and tumor response (CR/PR) are significant 
predictors of survival.
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